Could an Immune-Modulating drug slow early Alzheimer's?

NCT ID NCT04032626

Completed Disease control Sponsor: St. Joseph's Hospital and Medical Center, Phoenix Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial investigates whether lenalidomide, a drug that calms inflammation, can slow cognitive decline in people with mild cognitive impairment due to Alzheimer's disease. Participants take lenalidomide or a placebo for up to 12 months, followed by a 6-month washout period. The study measures changes in memory, daily function, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide
What this could lead to: If successful, this could point toward a new way to treat early Alzheimer's by calming inflammation in the brain and body.
What could go wrong: This is a small, early-phase trial with only 15 participants, so results may not apply widely. Lenalidomide can cause blood-related side effects, and the drug may not improve cognition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID PLAQUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease cognitive disorder Cognitive Dysfunction encephalitis Nerve Degeneration neurodegenerative disease Plaque, Amyloid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID PLAQUE COGNITIVE DYSFUNCTION COGNITIVE IMPAIRMENT, MILD INFLAMMATION, BRAIN NEURODEGENERATION

Contacts and locations

Locations

Cleveland Clinic Lou Ruvo Center for Brain health

Las Vegas, Nevada, 89103, United States
St. Joseph's Hospital and Medical Center

Phoenix, Arizona, 85013, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.